Overview
Pet diagnostics firm's Q1 revenue rose 14%, beating analyst expectations
Q1 EPS increased 17% to $3.47, driven by strong commercial performance
Company raised 2026 revenue and EPS outlook on strong CAG Diagnostics demand
Outlook
IDEXX raises 2026 revenue guidance to $4.68 bln-$4.76 bln, up $42 mln at midpoint
Company lifts 2026 EPS outlook to $14.45-$14.90, up $0.13 at midpoint
IDEXX now sees 2026 organic revenue growth of 7.7%-9.7%, up from 7.0%-9.0%
Result Drivers
CAG DIAGNOSTICS GROWTH - Double-digit recurring revenue gains in Companion Animal Group, supported by strong commercial execution, volume growth, and innovation
INTERNATIONAL AND U.S. CONTRIBUTIONS - International regions saw 21% reported and 12% organic CAG Diagnostics recurring revenue growth; U.S. growth aided by easing clinical visit pressures and increased diagnostic frequency
Company press release: ID:nBw18HPk8a
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$1.14 bln
$1.11 bln (12 Analysts)
Q1 EPS
$3.47
Q1 Gross Margin
63.40%
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)